

## Cangrelor

<b>Indication</b>	In combination with aspirin for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y <sub>12</sub> inhibitor (e.g. clopidogrel, prasugrel, ticagrelor) prior to the PCI procedure and in whom oral therapy with a P2Y <sub>12</sub> inhibitor is not suitable																												
<b>Dose</b>	<p>The treatment should be started <b>before</b> percutaneous coronary intervention.</p> <p>Initially a bolus of 30micrograms/kg is to be given, followed by an intravenous infusion of 4micrograms/kg/minute.</p> <p>The infusion should be continued for at least 2 hours or for the duration of the procedure, whichever is longer.</p> <p>The <b>maximum</b> duration of the infusion is 4 hours</p>																												
<b>Preparation</b>	Cangrelor 50mg vials																												
<b>Administration</b>	<ol style="list-style-type: none"> <li>1. Reconstitute 50mg vial with 5mL water for injection. Swirl gently until powder is dissolved, avoiding vigorous mixing. Allow any foam to settle. This will produce a 10mg per mL solution.</li> <li>2. Draw up 5mL (50mg) from the reconstituted vial and add to a 250mL bag of sodium chloride 0.9% or glucose 5% to produce a 200micrograms per mL solution</li> </ol> <p>The bolus dose should administered rapidly (&lt;1 minute) from the diluted infusion. The bolus should be completely administered prior to the start of the PCI.</p> <p>The infusion should be started straight after the bolus is given. Patients weighing over ≥100kg will need a minimum of two bags.</p>																												
<b>Shelf-life</b>	12 hours at room temperature																												
<b>Common Compatibility Issues</b>	<b>Do not</b> mix with any other medicines or infusion solutions																												
<b>Additional information</b>	Patients should be transitioned to oral P2Y <sub>12</sub> therapy for chronic treatment. For transition, a loading dose of (clopidogrel, ticagrelor, prasugrel) should be administered immediately following discontinuation of cangrelor infusion. Alternatively, a loading dose of ticagrelor or prasugrel ( <b>not</b> clopidogrel) may be administered up to 30 minutes before the end of the infusion.																												
<b>Sample Label</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="4" style="background-color: yellow; text-align: center;">DRUGS ADDED TO THIS INFUSION</th> </tr> </thead> <tbody> <tr> <td colspan="3">PATIENT <i>A. Patient (A. Number)</i></td> <td>WARD <i>Cath Lab</i></td> </tr> <tr> <td>DRUG <i>Cangrelor</i></td> <td>AMOUNT <i>50mg</i></td> <td>AD D BY</td> <td>CHECKED BY</td> </tr> <tr> <td colspan="2">In 250ml NaCl 0.9% / Glucose 5%</td> <td>EXP. DATE</td> <td>BATCH No.</td> </tr> <tr> <td colspan="2">DATE ADDED</td> <td>EXP. TIME</td> <td></td> </tr> <tr> <td colspan="2">TIME ADDED</td> <td></td> <td></td> </tr> <tr> <td colspan="4" style="text-align: center; background-color: yellow;"><b>DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS</b></td> </tr> </tbody> </table>	DRUGS ADDED TO THIS INFUSION				PATIENT <i>A. Patient (A. Number)</i>			WARD <i>Cath Lab</i>	DRUG <i>Cangrelor</i>	AMOUNT <i>50mg</i>	AD D BY	CHECKED BY	In 250ml NaCl 0.9% / Glucose 5%		EXP. DATE	BATCH No.	DATE ADDED		EXP. TIME		TIME ADDED				<b>DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS</b>			
DRUGS ADDED TO THIS INFUSION																													
PATIENT <i>A. Patient (A. Number)</i>			WARD <i>Cath Lab</i>																										
DRUG <i>Cangrelor</i>	AMOUNT <i>50mg</i>	AD D BY	CHECKED BY																										
In 250ml NaCl 0.9% / Glucose 5%		EXP. DATE	BATCH No.																										
DATE ADDED		EXP. TIME																											
TIME ADDED																													
<b>DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS</b>																													

Weight of patient (Kg)	Loading dose 30micrograms/Kg		Maintenance Infusion: 4microgram/kg/minute (0.24mg/kg/hr)	
	Loading dose in mg	Loading dose in mL	Dose per hour	Infusion rate: mL per hour
40	1.2mg	6mL	9.6mg/hr	48ml/hour
50	1.5mg	7.5mL	12mg/hr	60ml/hour
60	1.8mg	9mL	14.4mg/hour	72ml/hour
70	2.1mg	10.5mL	16.8mg/hour	84ml/hour
80	2.4mg	12mL	19.2mg/hour	96ml/hour
90	2.7mg	13.5mL	21.6mg/hour	108ml/hour
100	3.0mg	15mL	24mg/hour	120ml/hour
110	3.3mg	16.5mL	26.4mg/hour	130ml/hour
120	3.6mg	18mL	28.8mg/hour	144ml/hour
130	3.9mg	19.5mL	31.2mg/hour	156ml/hour
140	4.2mg	21mL	33.6mg/hour	168ml/hour
150	4.5mg	22.5mL	36mg/hour	180ml/hour

### **References**

- Kengrexal (cangrelor) Summary of Product Characteristics. Accessed on 04/12/2023
- ASHP Injectable Drugs Information. Accessed by November 2023
- British National Formulary. Accessed by [www.medicinescomplete.com](http://www.medicinescomplete.com)
- Brayfield A (ed), Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press <<http://www.medicinescomplete.com/>> (accessed November 2023).

**Written by** Mustafa Mohamed, Senior Rotational Pharmacist  
**Reviewed by** Dominic Moore, Advanced Pharmacist –Specialist Medicine  
Hester Smail (Advanced Pharmacist - Cardiology) November 2023  
**Approved by** Damian Kelly, Lead Clinician, Cardiology.  
Medical Division, 18/5/18

**For review November 2026**